SUNDAY, March 10 (HealthDay News) -- A newer class of diabetes
drugs may offer an extra benefit: A new study suggests these
medications lower the odds of suffering heart failure.
Researchers from Henry Ford Hospital in Detroit found that
patients taking so-called GLP-1 drugs -- including brand-name
medications such as Byetta, Januvia and Victoza -- were more than
40 percent less likely to be hospitalized for heart failure than
patients prescribed other blood sugar-lowering medications. GLP-1
diabetes drugs have been in use for only the last several years and
are considered second-line treatments after well-established
medications such as metformin, physicians said.
"I don't think we can say this will magically prevent all heart failure deaths, but the strength of the association warrants more investigation," said study author and cardiologist Dr. David Lanfear. "Heart failure is a very common disease . . . but something about diabetics make them definitely at increased risk for developing heart failure."
The study is to be presented Sunday at the American College of
Cardiology's annual meeting in San Francisco. Evidence presented at
medical meetings has not been peer-reviewed and is considered
According to the U.S. National Institutes of Health, about 6
million Americans suffer from heart failure, which occurs when the
heart can't efficiently pump blood through the body. Diabetics, who
now number 25 million in the United States, are between two and
four times more likely than those without the condition to die of
heart disease, which includes heart attacks, heart failure and
other cardiac problems.
In the retrospective study, Lanfear and his colleagues examined
data from more than 4,400 patients taking diabetes medications
between 2000 and 2012. About 1,500 were taking GLP-1 medications
and nearly 3,000 were not.
Over an average nine-month follow-up period, patients taking
GLP-1 medications were 41 percent less likely than others to be
hospitalized with heart failure. Additionally, these patients were
44 percent less likely to be hospitalized for any reason, and 80
percent less likely to die of any cause.
But neither Lanfear nor a doctor not involved with the research
could point to reasons why this newer class of diabetes drugs seems
to dampen the risk of heart failure.
"We don't know the mechanism yet. It's under active investigation," Lanfear said. "There are clues, but they would be a guess."
Lanfear noted that of the total 20,000 patients at Henry Ford
Hospital identified as taking diabetes drugs during the study
period, only about 1,500 were taking GLP-1 medications, or about 7
"We were surprised a little bit by the strength of the association [between the GLP-1 drugs and lower heart failure], but the results still need to be confirmed by other studies," he said. "We can't take this as an endorsement of these drugs."
Calling the study promising, Dr. David Friedman, chief of heart
failure services at North Shore-LIJ's Plainview Hospital in
Plainview, N.Y., said future research should be prospective instead
of analyzing past data.
"Heart failure is a huge problem among diabetics. Every year, there are about a half-million new heart failure patients, and a tremendous portion are those who've survived heart attacks and a fair number have diabetes," Friedman said.
"With diabetes and obesity issues constantly on the radar now, and with the onset of more heart failure cases, we need to find more novel approaches," he added. "If we can improve outcomes in this way, we'll have more hope for these patients."
The U.S. National Institutes of Health offers more information
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.